Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05845645 · ClinicalTrials.gov registry record · Phase 1
A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B
A Phase 1 study, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
NCT05845645 is a Phase 1 study that has completed, run by UCB Biopharma SRL. The registered enrollment target is 73 participants.
The verdict
NCT05845645, a Phase 1 study, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
Study Summary
The purpose of the study is to estimate the relative bioavailability of 2 new UCB0599 formulations under elevated and normal gastric pH conditions in healthy participants (Part A) and to asess the safety, tolerability and pharmacokinetics of UCB0599 in healthy participants of Japanese and Chinese origins (Part B).
Interventions
- OTHER Placebo
- DRUG UCB0599
- OTHER Esomeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2023-05-31 |
| Est. Completion | 2024-04-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05845645
The ClinicalTrials.gov registry entry for NCT05845645 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05845645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05845645 about?
NCT05845645 is a clinical study titled "A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B". The purpose of the study is to estimate the relative bioavailability of 2 new UCB0599 formulations under elevated and normal gastric pH conditions in healthy participants (Part A) and to asess the safety, tolerability and pharmacokinetics of UCB0599 in healthy participants of Japanese and Chinese or...
What is the current status of trial NCT05845645?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2023-05-31. Estimated completion is 2024-04-13.
What interventions are being tested in trial NCT05845645?
The interventions under investigation include: Placebo (OTHER), UCB0599 (DRUG), Esomeprazole (OTHER).
Who is sponsoring clinical trial NCT05845645?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.